Successful chemo-endocrine therapy for multiple bone metastases and myelophthisis caused by occult breast carcinoma

被引：1

作者：

Kanno M. ^{[1
]}

Nakamura S. ^{[2
]}

Uotani C. ^{[1
]}

Yamanaka S. ^{[1
]}

Terasaki Y. ^{[2
]}

Taniya T. ^{[3
]}

Yonezawa T. ^{[4
]}

Yonezawa K. ^{[4
]}

Watanabe K. ^{[5
]}

机构：

[1] Department of Internal Medicine, NTT West Corporation Kanazawa Hospital, 2-16-76 Owari-cho

[2] Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa

[3] Futaba Breast Clinic, Kanazawa

[4] Yonezawa Hospital of Orthopedics, Kanazawa

[5] Department of Pathology, National Kanazawa Hospital, Kanazawa

来源：

International Journal of Clinical Oncology | 2000年 / 5卷 / 6期

关键词：

Chemotherapy; Complete response; Endocrine therapy; Metastatic breast carcinoma; Occult breast carcinoma;

D O I：

10.1007/PL00012070

中图分类号：

学科分类号：

摘要：

We report a 55-year-old postmenopausal woman with occult breast carcinoma with multiple bone metastases and myelophthisis in whom complete response (CR) was achieved with chemo-endocrine therapy. At the time of admission, she had anemia and left axillary lymph node enlargement, with extremely high levels of serum tumor markers and no breast mass on physical examination or on a mammogram. Roentgenograms and bone scintigrams showed multiple bone, lung, and pleural metastases. Bone marrow biopsy and aspiration cytology from the left axillary lymph node revealed an invasion of adenocarcinoma cells. On immunohistochemical staining, the cancer cells were positive for estrogen receptor (ER), progesterone receptor (PgR), and gross cystic disease fluid protein-15 (GCDFP-15). CR was induced with a combination chemotherapy of doxorubicin, cyclophosphamide, and 5-fluorouracil (CAF), and has been maintained with sequential docetaxel administration with endocrine therapy. Her performance status (Eastern Cooperative Oncology Group) improved from 4 to 0. This patient represents a very specific and rare case in whom a primary tumor could not be detected despite severe advanced breast carcinoma, and in whom CR was achieved by chemo-endocrine therapy.

引用

页码：399 / 404

页数：5

共 17 条

[11] Ormsby A.H., Snow J.L., Su W.P., Et al., Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: A statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein, J Am Acad Dermatol, 32, pp. 711-716, (1995)
[12] Katagiri H., Takahashi M., Inagaki J., Et al., Determining the site of the primary cancer in patient with skeletal metastasis of unknown origin: A retrospective study, Cancer, 86, pp. 533-537, (1999)
[13] Stevens K.J., Smith S.L., Denley H., Et al., Is mammography of value in women with disseminated cancer of unknown origin?, Clin Oncol (R Coll Radiol), 11, pp. 90-92, (1999)
[14] Redding W.H., Monaghan P., Imrie S.F., Et al., Detection of micrometastases in patients with primary breast cancer, Lancet, 2, pp. 1271-1273, (1983)
[15] Cote R.J., Rosen P.P., Hakes T.B., Et al., Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease, Am J Surg Pathol, 12, pp. 333-340, (1988)
[16] Miller K.D., McCaskill-Stevens W., Sisk J., Et al., Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group, J Clin Oncol, 17, pp. 3033-3037, (1999)
[17] Buzdar A.U., Smith R., Vogel C., Et al., Fadrozole HCL (CGS 16949 A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials, Cancer, 77, pp. 2503-2513, (1996)

← 1 2 →